Skip to main content

Regenerative Medicine Market Size Expected to Reach USD 153.05 Billion, exhibiting a CAGR of 26.3% by 2029

As per the report by Fortune Business Insights, the global Regenerative Medicine Market size is projected to reach USD 153.05 billion in 2029, at a CAGR of 26.3% during the forecast period, 2022-2029

Pune, India, April 11, 2023 (GLOBE NEWSWIRE) — The global Regenerative Medicine Market size was USD 23.65 billion in 2021. The market is expected to grow from 29.86 billion in 2022 to USD 153.05 billion by 2029, exhibiting a CAGR of 26.3% during the forecast period. The market growth is anticipated to be driven by the emergence of a new range of opportunities due to the escalating prevalence of chronic genetic disorders. The market is expected to be propelled by its growing utilization in various fields such as cardiology, neurology, and oncology. Moreover, the market is projected to receive assistance in its development from the rising number of research initiatives and investments. These details have been provided by Fortune Business Insights in its report titled “Regenerative Medicine Market, 2022-2029”.

Industry Development:

June 2022- Bristol Myers Squibb Company received the U.S. FDA approval for CAR T cell Therapy Breyanzi. It is for people who have primary refractory or relapsed Large B-cell Lymphoma (LBCL) who cannot have transplants.


Request a Free Sample Copy of the Research Report:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/regenerative-medicine-market-100970


Report Scope & Segmentation

Report CoverageDetails
Forecast Period2022 to 2029
Forecast Period 2022 to 2029 CAGR26.3%
2029 Value ProjectionUSD 153.05 billion
Base Year2021
Market Size in 2021USD 23.65 billion
Historical Data2018-2020
No. of Pages192


Key Takeaways from the Regenerative Medicine Market:

  • Growth opportunities are expected to be provided by strategic acquisitions carried out by key players in the market.
  • The growth of the regenerative medicine market will be driven by innovative product launches resulting from the increasing investments in R&D activities.
  • Cell therapy, gene therapy, tissue engineering, and platelet-rich plasma are included in the global market based on their products.
  • In 2021, the market size of North America was valued at USD 10.50 billion.

Driving factor:

Market development will be propelled by an increased number of R&D activities focusing on new therapies.

The growth of the regenerative medicine market is expected to be fueled by an increasing number of investments in R&D activities aimed at developing new therapies and products, which will also facilitate significant mergers, partnerships, and research collaborations. To treat a range of chronic diseases such as cancers, Parkinson’s disease, diabetes, renal diseases, and cardiovascular diseases, among others, a variety of private and government players and research institutes have introduced options. Additionally, the market growth is expected to be driven by various applications of the product in cardiology, neurology, oncology, and other fields.


Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/regenerative-medicine-market-100970


Segmentation:

Cell therapy is expected to lead the market due to its increasing benefits in treating various diseases including autoimmune diseases, cancers, infectious diseases, and joint injuries. In 2021, cell therapy accounted for the largest share among the products segmented, according to their application, including gene therapy, tissue engineering, and platelet-rich plasma.

The orthopedics segment held the largest share of the global regenerative medicine market in 2021, based on its application, which is categorized into wound care, oncology, rare diseases, orthopedics, and others. This was due to a gradual increase in the prevalence of osteoarthritis and bone-related injuries.

Hospitals are expected to dominate the market during the forecast period based on the distribution channel. This is due to the increasing number of surgeries and government support and initiatives. The market is segmented into hospitals, clinics, and others.

Regional insights:

The market is expected to be led by North America due to the increasing technological innovations.

Due to technological innovations, rapid adoption of cell and gene therapy, and new product approvals, North America is expected to dominate the market share. Europe is expected to have the second-largest market share in the forecast period, with emerging government guidelines and therapies. Additionally, the presence of numerous research institutes and increasing government funding is expected to boost the market growth in Europe.

Asia Pacific is projected to exhibit the maximum compound annual growth rate (CAGR) due to rising cases of chronic diseases, government initiatives for technological advancements, and improving disposable incomes.

Report Coverage

The report offers: 

  • Major growth drivers, restraining factors, opportunities, and potential challenges for the market. 
  • Comprehensive insights into regional developments. 
  • List of major industry players. 
  • Key strategies adopted by the market players. 
  • Latest industry developments include product launches, partnerships, mergers, and acquisitions.    

Competitive Landscape

Key players are adopting partnership strategies to progress the market route.

Predictions suggest that partnership strategies by regenerative medicine players will strengthen the market’s grip. Gilead Sciences Inc. and Novartis AG are dominant companies in the cell and gene therapy segments, owing to their CAR T-cell therapy pipeline. In August 2022, bluebird bio received FDA approval for Zynteglo (betibeglogene autotemcel), which is the first cell-based gene therapy that can be used to treat adult and pediatric patients suffering from beta-thalassemia who regularly require red blood cell transfusions.


Quick Buy – https://www.fortunebusinessinsights.com/checkout-page/100970


The Report Lists the Key Companies in the Regenerative Medicine Market:

  • Integra LifeSciences Corporation (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Tissue Regenix (U.K.)
  • Smith & Nephew (U.K.)
  • MIMEDX (U.S.)
  • Novartis AG (Switzerland)
  • Allergan Aesthetics (AbbVie Inc.) (U.S.)
  • Stryker (U.S.)
  • American CryoStem Corporation (U.S.)
  • Kite (Gilead Sciences, Inc.) (U.S.)
  • AlloSource (U.S.)
  • bluebird bio, Inc. (U.S.)
  • CRISPR Therapeutics (Switzerland)
  • Janssen Global Services, LLC (Johnson & Johnson Services, Inc.) (Belgium)
  • Tegoscience (South Korea)

Some major points from Table of Content:

  • North America Regenerative Medicine Market Analysis, Insights and Forecast, 2019-2029
    • Market Analysis, Insights and Forecast – By Product
      • Cell Therapy
      • Gene Therapy
      • Tissue Engineering
      • Platelet Rich Plasma
    • Market Analysis, Insights and Forecast – By Application
      • Orthopedics
      • Wound Care
      • Oncology
      • Rare Diseases
      • Others
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospitals
      • Clinics
      • Others
    • Market Analysis, Insights and Forecast  – By Country
      • U.S.
      • Canada
  • Europe Regenerative Medicine Market Analysis, Insights and Forecast, 2018-2029
    • Market Analysis, Insights and Forecast – By Product
      • Cell Therapy
      • Gene Therapy
      • Tissue Engineering
      • Platelet Rich Plasma
    • Market Analysis, Insights and Forecast – By Application
      • Orthopedics
      • Wound Care
      • Oncology
      • Rare Diseases
      • Others
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospitals
      • Clinics
      • Others

TOC Continued…


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/clinical-trials-market-106930


Related Links:

Bone Graft Substitutes Market Size, Share, Growth Industry Report, 2020-2027

Orthobiologics Market Share, Size, Demand and Forecast

Revenue Cycle Management Market Size, Share, Growth Industry Report

Prefilled Syringes Market Share, Size, Demand and Forecast 2022-2029

Molecular Diagnostics Market Size, Share, Growth Industry Report

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.